“…CC and CXC chemokines are produced by most tumor cells, such as breast, cervix, pancreatic, and ovarian tumor cells ( 57 ). To provide optimal protection against tumor cells, the cytotoxic Vγ9Vδ2-T cells must migrate from the bloodstream to tumor site ( 33 , 100 , 101 ) (Figure 2 ). Unlike Vδ1 γδ-T cells which express lymph node homing chemokine receptor C-C chemokine receptor 7 (CCR7), the circulating Vγ9Vδ2-T cells preferentially express inflammatory homing chemokine receptor CCR5, which can mediate the migration of Vγ9Vδ2-T cells to CCR5 ligands that are expressed in tumor cells ( 20 , 102 ).…”